The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …

Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Cancer immunotherapy with chimeric antigen receptor (CAR) T cells can cause immune
effector cell-associated neurotoxicity syndrome (ICANS). However, the molecular …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

PURPOSE Children's Oncology Group trial AALL1621 was conducted to prospectively
determine the safety and efficacy of inotuzumab ozogamicin (InO) in pediatric and …